CURLF · Curaleaf Holdings, Inc.
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Jun 5, 2026; bars on opposite sides are not compared.
The closing range begins at the captured split on Jun 5, 2026.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 5, 2026TL;DR. Curaleaf posted Q2 revenue of $340M (up 10% YoY) with 50% gross margin and $70M adjusted EBITDA, swung to net income of $12.5M, and guided Q3 revenue to ~$347M (low-single-digit sequential growth) amid macro caution.
- + Q2 revenue grew 10% YoY to $340M, beating guidance
- + Gross margin expanded to 50%, up 170 bps YoY
- + International revenue grew 26% YoY led by UK, Germany, Poland
- + Swung to $12.5M net income from continuing operations vs. $48M loss YoY
- − Q3 revenue guided to low-single-digit sequential growth implying ~$347M, signaling caution
- − Adjusted EBITDA margin declined to 21% (120 bps YoY) due to international drag and SG&A pressure
- − Core SG&A rose $15M YoY to $115M, pressuring leverage
- − Six-month gross margin declined 80 bps YoY to 49%
- − International gross margin fell 20 bps sequentially to 42% on German price compression
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CURLF
this stock
Curaleaf Holdings, Inc.
|
$2.53B | — | -5.0% | — | 0.2% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$58.31B | +17.1% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$44.03B | -8.9% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$43.22B | +18.8% | +4.3% | 60.8 | 3.2% |
|
HLN
Haleon plc
|
$40.41B | -9.1% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Jun 5, 2026; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CURLF | +1.1% | -1.0% | — | -1.3% | — |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | +2.2% | +0.7% | — | -1.0% | — |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.